Is it possible that research continues to be done on MABs because there is also a belief that AD is a complex disease and a successful MAB might be used in a combination therapy? In the process they might be thinking that, who knows, but their therapy might indeed beat the SOC? It might not be a great business plan but it was all I can come up with for why research might continue with MABs.
Market Data 
Markets 
AI
